New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
With psilocybin among the favorites within psychedelics,
Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics
Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.
Psychedelics Funding At Its Best: $1.5M Destined To Psilocin Clinical Trials In Australia
Psychedelics biopharma company Lobe Sciences Ltd.
Nasdaq-listed Bright Minds Closes $4 Million Offering And Begins Dosing In Clinical Trial For Epilepsy
Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million.
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
Adastra Steps Into Magic Mushrooms! Gets Dealer’s License For Psilocybin And Psilocin
Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) has received its Controlled Drug and Substances Dealer's License on August 24, 2022. This license allows Adastra to process psilocybin and psilocin, the active compounds derived from psychedelic mushrooms.
First International Psilocybin Supply Agreement For Optimi Health: Here Are The Details
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural psilocybin and other psychedelic substances, announced that it has entered into its first international psi
World Class Leaders In Psychedelics Form Benzinga’s Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and